Cargando…

Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics

Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VH...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, Mark R, Maher, Eamonn R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092110/
https://www.ncbi.nlm.nih.gov/pubmed/20815920
http://dx.doi.org/10.1186/gm180
_version_ 1782203354812776448
author Morris, Mark R
Maher, Eamonn R
author_facet Morris, Mark R
Maher, Eamonn R
author_sort Morris, Mark R
collection PubMed
description Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VHL), the mutation frequency rates of known tumor suppressor genes in RCC are generally low, but the number of genes found to show frequent inactivation by promoter methylation in RCC continues to grow. Here, we review the genes identified as epigenetically silenced in RCC and their relationship to pathways of tumor development. Increased understanding of RCC epigenetics provides new insights into the molecular pathogenesis of RCC and opportunities for developing novel strategies for the diagnosis, prognosis and management of RCC.
format Text
id pubmed-3092110
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30921102011-09-03 Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics Morris, Mark R Maher, Eamonn R Genome Med Review Aberrant DNA methylation, in particular promoter hypermethylation and transcriptional silencing of tumor suppressor genes, has an important role in the development of many human cancers, including renal cell carcinoma (RCC). Indeed, apart from mutations in the well studied von Hippel-Lindau gene (VHL), the mutation frequency rates of known tumor suppressor genes in RCC are generally low, but the number of genes found to show frequent inactivation by promoter methylation in RCC continues to grow. Here, we review the genes identified as epigenetically silenced in RCC and their relationship to pathways of tumor development. Increased understanding of RCC epigenetics provides new insights into the molecular pathogenesis of RCC and opportunities for developing novel strategies for the diagnosis, prognosis and management of RCC. BioMed Central 2010-09-03 /pmc/articles/PMC3092110/ /pubmed/20815920 http://dx.doi.org/10.1186/gm180 Text en Copyright ©2010 BioMed Central Ltd.
spellingShingle Review
Morris, Mark R
Maher, Eamonn R
Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
title Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
title_full Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
title_fullStr Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
title_full_unstemmed Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
title_short Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
title_sort epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3092110/
https://www.ncbi.nlm.nih.gov/pubmed/20815920
http://dx.doi.org/10.1186/gm180
work_keys_str_mv AT morrismarkr epigeneticsofrenalcellcarcinomathepathtowardsnewdiagnosticsandtherapeutics
AT mahereamonnr epigeneticsofrenalcellcarcinomathepathtowardsnewdiagnosticsandtherapeutics